Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Budde

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
Blood Advances|July 24, 2025
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysisNausheen Ahmed, Swetha Thiruvengadam, Mehdi Hamadani, et al.
Nature Medicine|June 12, 2024
PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trialTanya B Dorff, M Suzette Blanchard, Lauren N Adkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2025
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO TrialLihua E Budde, Huilai Zhang, Won-Seog Kim, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 14, 2019
Management of Immunotherapy-Related Toxicities, Version 1.2019John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Annals of Hematology|July 25, 2021
Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter studyWon Seog Kim, Yasuhiro Oki, Seok Jin Kim, et al.
Blood Advances|June 24, 2026
CAR T Cell Therapy as a Definitive Consolidation for Older Adults with B-ALL in First Complete RemissionIbrahim Aldoss, Lior Goldberg, Jianying Zhang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2020
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 7, 2022
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in OncologyJohn A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Blood Advances|August 19, 2025
International Consensus Guidelines for the Conduct and Reporting of CAR T-Cell Clinical Trials in AMLSwati Naik, Richard Aplenc, Susanne H C Baumeister, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 13, 2024
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Blood Advances|July 24, 2025
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysisNausheen Ahmed, Swetha Thiruvengadam, Mehdi Hamadani, et al.
Nature Medicine|June 12, 2024
PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trialTanya B Dorff, M Suzette Blanchard, Lauren N Adkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2025
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO TrialLihua E Budde, Huilai Zhang, Won-Seog Kim, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 14, 2019
Management of Immunotherapy-Related Toxicities, Version 1.2019John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Annals of Hematology|July 25, 2021
Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter studyWon Seog Kim, Yasuhiro Oki, Seok Jin Kim, et al.
Blood Advances|June 24, 2026
CAR T Cell Therapy as a Definitive Consolidation for Older Adults with B-ALL in First Complete RemissionIbrahim Aldoss, Lior Goldberg, Jianying Zhang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2020
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 7, 2022
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in OncologyJohn A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Blood Advances|August 19, 2025
International Consensus Guidelines for the Conduct and Reporting of CAR T-Cell Clinical Trials in AMLSwati Naik, Richard Aplenc, Susanne H C Baumeister, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 13, 2024
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Pageof 10